Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary IndicationPETACH TIKVA, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Nanox.ARC, a stationary X-ray system intended to produce tomographic images for general use including human musculoskeletal system, pulmonary, intra-abdominal, and paranasal sinus indications, adjunctive to conventional radiography, on adult patients.
Nanox Announces Third Quarter of 2024 Financial Results and Provides Business UpdateMade progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI
Nanox to Report Third Quarter and Financial Results on November 21, 2024PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox Highlighted on TIME's Best Inventions of 2024 List for its AI SolutionsNanox AI’s Solutions selected for Special Mention on annual list recognizing the most impactful new products and ideas
Nanox to Participate in Upcoming Investor Conference in September 2024PETACH TIKVA, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that Company management will participate in an investor conference in the month of September 2024:
Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery CalciumHealthCCSng V2.0 introduces additional ‘zero calcium’ categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output
Nanox to Report Second Quarter and Financial Results on August 20, 2024PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Innovative Data Featuring Nanox AI Cardiac Solution Showcased at SCCT 2024In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner
Data Supporting Nanox.AI Cardiac Solution to Be Presented at 19th Annual Meeting of the Society of Cardiovascular Computed TomographyPETACH TIKVA, Israel, June 25, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography (SCCT), being held July 18-21 in Washington, D.C.
Nanox Launches Artificial Intelligence Functionality in Second Opinions PlatformNanox integrates FDA-cleared population health AI solutions into its Second Opinions service
Nanox to Report First Quarter and Financial Results on May 28, 2024PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox to Participate in Three Upcoming Investor Conferences in May 2024PETACH TIKVA, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announces that Company management will participate in three investor conferences in the month of May 2024:
Nanox Files 2023 Annual Report on Form 20-FPETACH TIKVA, Israel, April 22, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at https://www.sec.gov/ and on the Company’s website at https://www.nanox.vision/ under “Financials” in the Investors section.
Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean MarketAhealthZ to aid Nanox’s pursuit of local authorizations and licenses for Nanox.ARC in South Korea
Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business UpdateNanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging
Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (
NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold– According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average
Nanox and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest DiseasesFirst patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D tomographic images
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty LiverNanox’s HealthFLD is pioneering the use of a fully automated AI software for liver attenuation analysis from CT scans that has received FDA 510(k) clearance for use in general population
Nanox Mourns Death of Its Founder, Ran PoliakinePETACH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (
NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced that the Company’s founder and non-executive chairman, Ran Poliakine, passed away on Friday, Jan. 12, 2024, due to a medical condition. Mr. Poliakine was a serial entrepreneur who over the course of his 35-year career founded more than 20 companies, and gave rise to over 70 patents in his various fields of interest, including healthcare, social impact technology, the environment and industry.
Nanox to Report Third Quarter 2023 Financial Results on November 28, 2023 and Reschedules Investor Day for December 4, 2023NEVE ILAN, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (
NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2023 on November 28, 2023 at 8:30 a.m. ET. The Company also announced that it will hold its Investor Day on December 4, 2023, at the Nasdaq building in New York City.
Nanox Continues Business as Planned, and Postpones Investor Day Scheduled for October 17, 2023NEVE ILAN, Israel, Oct. 10, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (
NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that it is postponing the previously announced Investor Day scheduled for Tuesday, Oct. 17, 2023, at the Nasdaq in New York City.
Nanox Announces Strategic Manufacturing Agreement with Varex Imaging Corporation to Advance the Nanox.ARC Medical Imaging SystemNEVE ILAN, Israel and SALT LAKE CITY, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company today announced the entrance into a manufacture and supply agreement with Varex Imaging Corporation (“Varex,” Nasdaq: VREX), a leading innovator, designer and manufacturer of X-ray imaging components, under which Varex will supply X-ray tubes utilizing the Nanox digital X-ray source for the Nanox.ARC system. The agreement was entered into after Varex completed, over the last several months, an assessment of Nanox’s novel digital X-ray source.
Nanox to Host Investor Day on October 17, 2023NEVE ILAN, Israel, Oct. 02, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (
NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced it will host an Investor Day at the Nasdaq in New York City on Tuesday, October 17, 2023. The event will include presentations and Q&A with leaders from across the company.
Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTsBeilinson Hospital in Israel used Nanox.AI’s HealthCCSng solution to conduct study on routine chest CT scans to assess impact of AI-based coronary artery calcium (CAC) measurements
Nanox to Present at the Cantor Fitzgerald Global Healthcare Conference 2023 in SeptemberNEVE ILAN, Israel, Sept. 13, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (
NASDAQNNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2023, which will be held on September 26-28, 2023 at the InterContinental Barclay Hotel in New York City.
Nanox to Report Second Quarter 2023 Financial Results on August 17, 2023NEVE ILAN, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its financial results for the second quarter ended June 30, 2023 before market open on Thursday, August 17, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update on the same day at 8:30 a.m. ET.
Nanox Announces $30 Million Registered Direct OfferingNEVE ILAN, Israel, July 24, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,142,858 of the Company’s ordinary shares, par value NIS 0.01 per share (the “ordinary shares”), together with warrants to purchase up to 2,142,858 ordinary shares at a combined purchase price of $14.00 per share, in a registered direct offering. The warrants will have an exercise price of $19.00 per share, will be exercisable immediately upon issuance and will expire five years from issuance.
Nanox to Report First Quarter 2023 Financial Results on May 22, 2023NEVE ILAN, Israel, May 17, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its financial results for the first quarter ended March 31, 2023 before market on Monday, May 22, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical ImagingNEVE ILAN, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the multi-source Nanox.ARC, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system intended to produce tomographic images of the human musculoskeletal system adjunctive to conventional radiography on adult patients. Representing a major advancement in X-ray technology, Nanox.ARC is a multi-source digital 3D tomosynthesis system that utilizes novel, cold cathode X-ray tubes, which the Company intends to offer using an innovative pay-per-scan business model.
Nanox Files 2022 Annual Report on Form 20-FNEVE ILAN, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission (“SEC”) on May 1, 2023. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.nanox.vision under “Financials” in the Investors section.
Nanox.AI Expands Footprint Through New Global Partnership with Ferrum HealthPartnership with Ferrum Health offers unprecedented data security and an integrated AI platform to streamline health systems’ adoption of AI technology, such as Nanox’s Bone solution (HealthOST) and cardiac solution (HealthCCSng)
Nanox.AI Connects to Nuance Precision Imaging Network to Improve Early Detection of Chronic Diseases with Workflow-Integrated AIThe secure nationwide AI-powered cloud platform streamlines care team communication and delivers patient-specific imaging insights within clinical workflows
Nanox to Report Third Quarter 2022 Financial Results on November 10, 2022NEVE ILAN, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its financial results for the third quarter ended September 30, 2022 before market on Thursday, November 10, 2022. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox to Host and Livestream ‘ARC Day’ event: Company’s Demonstration of Nanox’s EcosystemARC Day will publicly demonstrate Nanox’s end-to-end 3D medical imaging solution in-person and online
USARAD, a Nanox Company, Achieves the Joint Commission Re-Certification
NANO-X IMAGING LTD. (“Nanox,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., one of the world’s leading teleradiology providers, has been re-certified with The Joint Commission's Gold Seal of Approval. The Joint Commission is the leading accrediting organization in the United States that certifies more than 22,000 health care organizations and programs based on the highest standards of patient safety and quality of care.
